Immunoassays News and Research

RSS

Lateral flow assays detect a compound of interest in a compact, paper-based system. Tests such as pregnancy tests are based on lateral flow assays, with many more available for various compounds or even pathogens.

VolitionRx enters into distribution agreement with Active Motif for NuQ product line

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, today entered into an agreement with Active Motif, a leading provider of kits and reagents to enable epigenetics research.

26 Sep 2013

65 metabolites in urine simultaneously measured by clinical IEM-by-NMR screening study in Turkey

At the 12th International Congress of Inborn Errors of Metabolism (www.iciem2013.com), Bruker announces another milestone in the cost-effective use of NMR (nuclear magnetic resonance) spectroscopy screening as a clinical research tool for metabolic screening and small molecule in vitro diagnostics (IVD) research and validation.

4 Sep 2013

GSD receives FDA Clearance for 25-OH Vitamin D Total ELISA test

Gold Standard Diagnostics, Corp., a leading manufacturer and marketer of clinical laboratory instrumentation and assays for the in vitro diagnostics market, announced 510k FDA Clearance of its 25-OH Vitamin D, Total ELISA.

24 Jul 2013

Plague detection through anti-carbohydrate antibodies could lead to rapid diagnosis

Even today, the lives of humans and animals are claimed by plague. A new antibody-based detection method can be used to reliably and sensitively identify plague in patient serum and other biological samples.

18 Jul 2013

Fetal exposure to BPA lowers testicular hormone in newborn boys

A new study links fetal exposure to a common chemical pollutant, bisphenol A (BPA), to defects of a testicular hormone in newborn boys with undescended testicles. The results, which were presented Monday at The Endocrine Society's 95th Annual Meeting in San Francisco, suggest yet another potential harmful effect of BPA, which is widely used in many plastics, liners of food cans and dental sealants.

18 Jun 2013

Matrix-Bio, Quest Diagnostics enter global licensing agreement for metabolomic biomarkers

Matrix-Bio, Inc., a diagnostics company that uses metabolite profiling to detect cancer and other diseases, has signed an exclusive global licensing and marketing agreement for metabolomic biomarkers with Quest Diagnostics, the world's leading provider of diagnostic information services. Under the agreement, Quest Diagnostics will have the rights to use the biomarkers for the future, potential development of a clinical lab-developed test to aid in the detection of breast cancer recurrence.

From Quest Diagnostics 12 Apr 2013

Agilent launches new application compendiums on designer drug testing and toxicology of oral fluids

Agilent Technologies Inc. today introduced new application compendiums on designer drug testing and toxicology of oral fluids.

5 Feb 2013

Thermo Scientific QMS Everolimus Assay Kit receives CE Mark for liver transplant application

Thermo Fisher Scientific Inc., the world leader in serving science, today announced that its Thermo Scientific QMS Everolimus Assay Kit has been CE marked for sale in the European Union for a third application, namely liver transplants.

From Thermo Fisher Scientific Inc. 16 Jan 2013

Range of epigenetic immunoassays from VolitionRx now available for research use

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests, announces the launch of NuQ, its range of research use only epigenetic immunoassays, to be available for sale at www.nucleosomics.com.

17 Dec 2012

DRG Diagnostics, BIT Analytical Instruments to launch new product

BIT Analytical Instruments, a complete contract product development, manufacturing services and after-sales service provider to medical and industrial instrument OEM clients, partnered with DRG Diagnostics to launch a revolutionary new product - the DRG:HYBRID XL Analyzer, a fully-automated and integrated random-access analyzer for immunoassays and clinical chemistry.

29 Aug 2012

T. gondii link to schizophrenia supported

Study results support an associated between maternal infection with Toxoplasma gondii and an increased risk for schizophrenia in offspring.

24 Jul 2012

Abbott to showcase new informatics and lab solutions at AACC annual meeting

Abbott will feature new solutions to improve data management and automation at this year's American Association for Clinical Chemistry (AACC) annual meeting, July 15-19, in Los Angeles, Calif. Solutions to further enhance efficiency and workflow in today's laboratories will be the focal point of the Abbott exhibit.

16 Jul 2012

New molecular test panel to enhance reliability of thyroid biopsy testing

Quest Diagnostics, the world's leading provider of diagnostic testing, information and services, today announced a new molecular test panel designed to help physicians determine if a thyroid gland is cancerous and requires surgical removal.

From Quest Diagnostics 2 Jun 2012

Breakthrough in nanotechnology could make laboratory tests more sensitive

A laboratory test used to detect disease and perform biological research could be made more than 3 million times more sensitive, according to researchers who combined standard biological tools with a breakthrough in nanotechnology.

2 Jun 2012

Quest Diagnostics introduces four new tests panels for CAH

Quest Diagnostics, the world's leading provider of diagnostic testing, information and services, has extended its endocrine diagnostics menu with the introduction of four new tests panels for congenital adrenal hyperplasia (CAH), an endocrine disorder found in newborns, children and women.

From Quest Diagnostics 19 May 2012

Affymetrix to acquire eBioscience

Affymetrix, Inc., and eBioscience, Inc., a privately-held San Diego, CA-based company with an industry-leading position in flow cytometry and immunoassay reagents for immunology and oncology research and diagnostics, today announced they have amended their existing definitive agreement dated November 29, 2011 under which Affymetrix will acquire eBioscience.

4 May 2012

Applied BioCode receives U.S. patent titled, ‘Light Transmitted Assay Beads’

Applied BioCode, Inc. today announced that the United States Patent and Trademark Office has issued US Patent #8,148,139 "Light Transmitted Assay Beads," describing the method of use and manufacturing of its Barcoded Magnetic Beads (BMB) products.

5 Apr 2012

MabCure retains CUNY CAT to evaluate monoclonal antibodies against ovarian cancer

MabCure Inc., a leading developer of antibody-based technology for the diagnosis and treatment of ovarian, prostate, colorectal and other cancers, has retained the CUNY Center for Advanced Technology (CUNY CAT) to evaluate its monoclonal antibodies against ovarian cancer cells as diagnostic reagents.

29 Mar 2012

New microfluidic chip more effective in detecting flu outbreaks

The H1N1 flu pandemic in 2009 underscored weaknesses in methods widely used to diagnose the flu, from frequent false negatives to long wait times for results. Now Boston University researchers have developed a prototype of a rapid, low-cost, accurate, point-of-care device that promises to provide clinicians with an effective tool to quickly diagnose both seasonal and pandemic strains of influenza, and thus limit the spread of infection.

28 Mar 2012

Affymetrix signs definitive agreement to acquire eBioscience

Affymetrix, Inc., today announced that it has signed a definitive agreement to acquire eBioscience, Inc., a privately-held San Diego, CA-based company with an industry-leading position in flow cytometry and immunoassay reagents for immunology and oncology research and diagnostics. Under the terms of the agreement, Affymetrix will acquire eBioscience for $330 million in cash subject to certain customary adjustments.

30 Nov 2011